Sign in

    Webcast Participant • N/A

    Webcast Participant's questions to St Joe Co (JOE) leadership

    Webcast Participant's questions to St Joe Co (JOE) leadership • Q2 2025

    Question

    A Webcast Participant asked about a range of topics including the drivers for the 482 newly contracted homesites, potential bottlenecks like interest rates, and the strategy for the Pigeon Creek development, specifically whether it could be sold to a single large builder. Questions also covered capital allocation, the reasons for a slight dip in club memberships despite revenue growth, the timeline for major projects like the FSU Health hospital and the West Bay Bridge, and the earnings potential of new ventures like the Watersound Real Estate brokerage.

    Answer

    President, CEO & Chairman Jorge Gonzalez explained that the pickup in homesite contracts was broad-based across all active communities, with the primary headwind being national mortgage rates. He confirmed active discussions with a single large builder interested in the entire Pigeon Creek DSAP to accelerate development. Regarding club metrics, Gonzalez attributed the slight membership dip to a significant, planned increase in entry fees and dues, which in turn drove higher club revenue. He noted that capital allocation remains dynamic, with a focus on shareholder value, and highlighted that the FSU hospital project is awaiting the finalization of an operator agreement before moving forward quickly.

    Ask Fintool Equity Research AI

    Webcast Participant's questions to STAAR Surgical Co (STAA) leadership

    Webcast Participant's questions to STAAR Surgical Co (STAA) leadership • Q1 2025

    Question

    A webcast participant questioned the decision to withdraw guidance, given positive commentary on China procedure trends and cost-cutting initiatives, asking if the outlook is now better than previously communicated.

    Answer

    CEO Steve Farrell explained that while the team is optimistic, global uncertainty and the evolving tariff situation necessitate caution. He emphasized the new management team's commitment to transparency and building trust by delivering on promises, preferring to be 'near certain' before issuing formal guidance. Farrell provided color on various components of the previous guidance, noting confidence in the China revenue range and cost controls, but acknowledging potential risks to the gross margin target due to the accelerated ramp-up of the Switzerland facility.

    Ask Fintool Equity Research AI

    Webcast Participant's questions to Know Labs Inc (KNW) leadership

    Webcast Participant's questions to Know Labs Inc (KNW) leadership • Q2 2024

    Question

    A webcast participant asked for details on the company's engagement and submission process with the FDA.

    Answer

    CEO Ron Erickson stated that Know Labs has already begun the process of 'socializing' its technology with the FDA. The next formal step is a pre-submission meeting, which the company aims to hold within fiscal year 2024. Following that meeting, the plan is to proceed with clinical trials for the refined Gen 2 device under FDA-organized protocols.

    Ask Fintool Equity Research AI